Source: Diabetes Care. Unidade: EEFERP
Subjects: ENVELHECIMENTO, GLICOSE, PRESSÃO SANGUÍNEA, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS INSULINO-DEPENDENTE, FARMACOTERAPIA
ABNT
TANG, Yaling et al. Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes: the ACCORD Trial. Diabetes Care, v. 44, n. 1, p. 164-173, 2021Tradução . . Disponível em: https://doi.org/10.2337/dc20-1842. Acesso em: 17 ago. 2024.APA
Tang, Y., Shah, H., Bueno Júnior, C. R., Sun, X., Mitri, J., Sambataro, M., et al. (2021). Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes: the ACCORD Trial. Diabetes Care, 44( 1), 164-173. doi:10.2337/dc20-1842NLM
Tang Y, Shah H, Bueno Júnior CR, Sun X, Mitri J, Sambataro M, Sambado L, Gerstein HC, Fonseca V, Doria A, Pop-Busui R. Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes: the ACCORD Trial [Internet]. Diabetes Care. 2021 ; 44( 1): 164-173.[citado 2024 ago. 17 ] Available from: https://doi.org/10.2337/dc20-1842Vancouver
Tang Y, Shah H, Bueno Júnior CR, Sun X, Mitri J, Sambataro M, Sambado L, Gerstein HC, Fonseca V, Doria A, Pop-Busui R. Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes: the ACCORD Trial [Internet]. Diabetes Care. 2021 ; 44( 1): 164-173.[citado 2024 ago. 17 ] Available from: https://doi.org/10.2337/dc20-1842